Recent Quotes (30 days)

You have no recent quotes
chg | %

ProMetic Life Sciences Inc.  

(Public, TSE:PLI)   Watch this stock  
Find more results for PLI
1.19
-0.02 (-1.65%)
Delayed:   11:28AM EDT
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.18 - 1.23
52 week 0.27 - 1.65
Open 1.22
Vol / Avg. 379,446.00/1.95M
Mkt cap 628.69M
P/E     -
Div/yield     -
EPS -0.02
Shares 528.31M
Beta 1.24
Inst. own     -
Mar 24, 2014
Q4 2013 ProMetic Life Sciences Inc. Earnings Release (Estimated)
Feb 11, 2014
ProMetic Life Sciences Inc. at Biotechnology Industry Organization CEO & Investor Conference
  

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin -88.98% -1.82%
Operating margin -88.98% -1.82%
EBITD margin - 10.71%
Return on average assets -89.90% -2.68%
Return on average equity -558.79% -
Employees 116 -
CDP Score - -

Address

Bldg 15, 531 Boul. des Prairies
LAVAL, QC H7V 1B7
Canada
+1-450-7810115 (Phone)
+1-450-7814477 (Fax)

Website links

Description

ProMetic Life Sciences Inc. (ProMetic) is a bio-pharmaceutical comnpany offering technologies for large-scale drug purification, drug development, proteomics, clinical diagnostics, and the elimination of pathogens, The Company focuses its activities in two segments: protein technologies and therapeutics. It develops therapeutics to treat blood-related disorders. Its protein technologies are used to remove pathogens from blood and extract and recover valuable proteins from plasma. The Company is developing products to treat anemia, neutropenia, cancer and autoimmune disease/inflammation, as well as certain nephropathies. ProMetic uses its Affinity Technology, which employs its Mimetic Ligand technology (chemical hooks that selectively recognize and bind to target biomolecules) to facilitate a variety of applications, where a target biomolecule requires purification or removal. In October 2009, it obtained a controlling stake in Pathogen Removal and Diagnostic Technologies Inc.

Officers and directors

G. F. Kym Anthony Independent Chairman of the Board
Age: 57
Pierre Laurin Ph.D. President, Chief Executive Officer, Director
Age: 52
Bruce Pritchard Chief Financial Officer
Steven J. Burton Chief Executive Officer of ProMetic BioSciences Ltd.
Patrick Sartore Senior Legal Counsel, Corporate Secretary
John Moran M.D. Chief Medical Officer, Director
Age: 67
Dwun-Hou Chen Ph.D. Senior Vice President, Product and Asia Pacific Development of ProMetic BioTherapeutics, Inc.
Bruce J. Wendel Director
Age: 59
Benjamin Wygodny Director
Age: 67
Robert Lacroix Ph.D. Independent Director
Age: 67